The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Phase I MD Anderson study shows YAP/TEAD inhibitor VT3989 is well tolerated and shows antitumor activity in advanced mesothelioma and NF2-mutant cancers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with NF2 mutations, according to results of a phase I trial led by researchers at MD Anderson Cancer Center. The first-in-human study was presented today at the 2023 American Association for Cancer Research annual meeting.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

MD Anderson’s Boot Walk to End Cancer raises $1.4M

The University of Texas MD Anderson Cancer Center hosted its ninth annual Boot Walk to End Cancer fundraising event on Nov. 2, in the Texas Medical Center. This year, the Boot Walk’s 7,000+ in-person participants and 1,200+ virtual participants from Houston and around the world joined together to raise $1.4 million to support the institution’s mission to end cancer. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account